Rockwell Medical (RMTI)
(Delayed Data from NSDQ)
$2.11 USD
+0.18 (9.07%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $2.10 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RMTI 2.11 +0.18(9.07%)
Will RMTI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RMTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RMTI
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
RMTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know
Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates
Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts
Other News for RMTI
Rockwell Medical to Release Second Quarter 2024 Results on Thursday, August 8, 2024
Rockwell Medical Promotes Tim Chole to Chief Commercial Officer
Rockwell Medical names Tim Chole as Chief Commercial Officer
Analysts Offer Insights on Healthcare Companies: Innovative Eyewear, Inc. (LUCY), Rockwell Med (RMTI) and Mereo Biopharma Group Plc (MREO)
Rockwell Medical: Strong Financial Performance and Strategic Partnerships Justify Buy Rating